Peer-influenced content. Sources you trust. No registration required. This is HCN.
Healthgrades for Professionals
Hormonal conditions like PMDD and menopause can trigger depression; tracking symptoms and using hormone therapy may significantly improve outcomes.
Family Medicine/General Practice July 1st 2025
Psychiatry Advisor
Quetiapine demonstrated superior symptom reduction with significantly lower healthcare costs and higher quality-adjusted life-years compared to lithium in routine clinical practice settings.
Psychiatry June 25th 2025
Psych Congress Network
“When it comes to trying to work out this issue of sleep problems and depression, it is a classic chicken and the egg problem… The question is, when we look at what’s causing what, that’s not just an idle sort of thing to think about. It has direct treatment implications.”
Geriatrics March 4th 2025
Epoch Health
“Don’t try to think yourself out of a dysregulated state; it’s a body thing.”
Psychiatry February 20th 2025
Medical Professionals Reference (MPR)
Rapid symptom improvement and sustained 4-week benefits distinguish Spravato monotherapy in treatment-resistant depression, with significant MADRS score reductions versus placebo.
Psychiatry February 5th 2025
MedCentral
The FDA-designated Class II recall affects specific duloxetine lots where exposure may lead to “temporary or medically reversible health consequences or where the probability of serious adverse health consequences is remote.”
Clinical Pharmacology November 20th 2024